NCT03427801View on ClinicalTrials.gov

Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney Disease

CompletedOBSERVATIONAL
Enrollment

78

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

December 1, 2018

Study Completion Date

December 30, 2018

Conditions
Anemia of Chronic Kidney Disease
Interventions
DRUG

Erythropoiesis-Stimulating Agent

erythropoiesis-stimulating agent: Mircera or Darbepoietin

Trial Locations (1)

SAR

Prince of Wales Hospital, Chinese University of Hong Kong, Shatin

All Listed Sponsors
lead

Chinese University of Hong Kong

OTHER

NCT03427801 - Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney Disease | Biotech Hunter | Biotech Hunter